Interleukin-1 receptor - Affymax

Drug Profile

Interleukin-1 receptor - Affymax

Latest Information Update: 18 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Interleukin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 14 Dec 2000 No-Development-Reported for Postmenopausal osteoporosis in USA (Injection)
  • 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
  • 02 Oct 1998 Investigation in Postmenopausal osteoporosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top